Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Georg Lerchen

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Chemmedchem|May 11, 2017
Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A<sub>1</sub> Receptor Agonist for the Chronic Treatment of Heart DiseasesDaniel Meibom, Barbara Albrecht-Küpper, Nicole Diedrichs, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 20, 2018
Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted ConjugateAndré Raposo Moreira Dias, Arianna Pina, Amelia Dean, et al.
Cancers|November 25, 2020
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic MalignanciesDennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, et al.
Cancer Research|August 21, 2016
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid TumorsAnette Sommer, Charlotte Kopitz, Christoph A Schatz, et al.
Molecular Cancer Therapeutics|March 16, 2017
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung CancerJörg Willuda, Lars Linden, Hans-Georg Lerchen, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Chemmedchem|May 11, 2017
Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A<sub>1</sub> Receptor Agonist for the Chronic Treatment of Heart DiseasesDaniel Meibom, Barbara Albrecht-Küpper, Nicole Diedrichs, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 20, 2018
Neutrophil Elastase Promotes Linker Cleavage and Paclitaxel Release from an Integrin-Targeted ConjugateAndré Raposo Moreira Dias, Arianna Pina, Amelia Dean, et al.
Cancers|November 25, 2020
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic MalignanciesDennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, et al.
Cancer Research|August 21, 2016
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid TumorsAnette Sommer, Charlotte Kopitz, Christoph A Schatz, et al.
Molecular Cancer Therapeutics|March 16, 2017
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung CancerJörg Willuda, Lars Linden, Hans-Georg Lerchen, et al.
Pageof 2